<DOC>
	<DOCNO>NCT01970878</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel group , chronic dosing , active-controlled , 28-week safety extension study two pivotal 24-week safety efficacy study ( Studies PT003006 PT003007 ) . This study design assess long-term safety tolerability Glycopyrrolate ( GP ) Formoterol Fumarate ( FF ) combination ( GFF ) meter dose inhaler ( MDI ) , GP MDI , FF MDI subject moderate severe COPD total observation period 52 week . Open-label Spiriva include active control . To eligible study , subject must complete participation Study PT003006 ( NCT01854645 ) Study PT003007 ( NCT01854658 ) .</brief_summary>
	<brief_title>Extension Study Evaluate Safety Efficacy PT003 , PT001 , PT005 Subjects With Moderate Very Severe COPD , With Spiriva® Handihaler® ( PINNACLE 3 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Key Participant in/completion previous 24week PINNACLE Phase III Trial . Male female subject least 40 year age old 80 Visit 1 . Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoking . Subjects FEV1/forced vital capacity ( FVC ) ratio &lt; 0.70 FEV1 &lt; 80 % predict normal ≥750 mL FEV1 &lt; 30 % predict normal value . Subjects willing , opinion investigator , able adjust current COPD therapy require protocol Key Significant diseases COPD , i.e . disease condition , opinion investigator , may put patient risk participation study may influence either result study subject 's ability participate study Current diagnosis asthma alpha1 antitrypsin deficiency Other active pulmonary disease active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , idiopathic interstitial pulmonary fibrosis , primary pulmonary hypertension , uncontrolled sleep apnea Hospitalized due poorly control COPD within 3 month prior screen Screening Period Poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior screen Screening Period Lower respiratory tract infection require antibiotic within 6 week prior screen Screening Period Unstable ischemic heart disease , leave ventricular failure , document myocardial infarction within 12 month enrollment . Recent history acute coronary syndrome , percutaneous coronary intervention , coronary artery bypass graft within past three month Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class III/IV ) Clinically significant abnormal 12lead electrocardiogram ( ECG ) Abnormal liver function test define alanine transaminase ( ALT ) , aspartate transaminanse ( AST ) , total bilirubin ≥ 1.5 time upper limit normal Visit 1 repeat test Cancer complete remission least five year History hypersensitivity β2agonists , glycopyrronium muscarinic anticholinergic , lactose/milk protein component MDI Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>